pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
Endpoints·4h ago·1 min read
save

Alphabet reshuffles AI leadership as DeepMind CEO steps down to become chief scientist

Aug 5, 2026·read at Endpoints ↗Neutral

Alphabet announced a reorganization of its artificial intelligence leadership. Demis Hassabis will leave his role as chief executive of Google DeepMind and take on the position of chief scientist for the parent company.

The change positions Hassabis to oversee AI research across Alphabet’s various units, while the former long-time Google chief scientist Jeff Dean is departing to start his own venture.

The move reflects Alphabet’s broader effort to streamline its AI strategy after recent internal shifts, though no specific projects or timelines were detailed.

source

This writeup was produced by pharmadog from original reporting by Endpoints.

Original headline: “Demis Hassabis 'leaning into' Isomorphic CEO role amid Alphabet's AI shakeup”

read at Endpoints ↗
98 words · retrieved 4h ago
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

no entities indexed yet

related stories

  • 1h agoFDA approves Takeda's orexin drug for narcolepsyEndpoints
  • 2h agoSenate confirms Erica Schwartz as CDC directorEndpoints
  • 4h agoAtossa Therapeutics founder to be selected as NIAID director — reportEndpoints
  • 4h agoIn a first, WuXi AppTec surpasses Lonza’s six-month revenueEndpoints
  • 8h agoArrowhead buys PRV for $215M; Twist hopes to raise $300M in public offeringEndpoints